Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

NCT04656691 is registered in ClinicalTrials.gov with Daniel Griffin as lead sponsor.

NCT NCT04656691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04656691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19
Lead sponsor
Daniel Griffin
Phase
Phase 4
Overall status
Terminated
Start date
January 4, 2021
Completion date
April 18, 2021
Enrollment
139 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19